We're still tracking some of the ways firms are working to optimize their portfolios and managing competitive strategy. This week we're looking at two M&A deals: Ono Pharma's agreement with Biohaven for IgG degraders and Gilead's deal with Vir Bio for T-cell engagers. For the regional rights to three of Biohaven’s IgG degraders, including a phase 3-stage Grave’s disease potential, Japan’s Ono Pharmaceutical is paying $80 million up front. Ono also agreed to a $20 million mi